x

Posted 25 May, 2023

AXIM BIOTECHNOLOGIES, INC. appointed new CEO

CEO Change detected for ticker OTC:AXIM in a 8-K filed on 25 May, 2023.


  On May 23, 2023, our Chief Executive Officer appointed Kurt Phinney as the Company's Chief Operating Officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of AXIM BIOTECHNOLOGIES, INC.
Health Care/Life Sciences • Biotechnology
AXIM Biotechnologies, Inc. operates as a biotechnology company, which engages in the development of diagnostic healthcare solutions. Its product categories include Eye Health, SARS-CoV-2, and fentanyl neutralizing antibody test. The company was founded on November 18, 2010 and is headquartered in San Diego, CA.
Market Cap
$4.18M
View Company Details
AXIM BIOTECHNOLOGIES, INC. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On May 23, 2023, our Chief Executive Officer appointed Kurt Phinney as the Company's Chief Operating Officer. 


Mr. Phinney's experience includes serving as the Quality and Regulatory Manager of Great Lakes Cheese; Sr. Director of Operations for Rapid Pathogen Screening; and R&D Scientist & Manufacturing Manger for Immunetics, Inc. Mr. Phinney received multiple honors and medals serving as a Corpsman in the United States Coast Guard (1989-1995); Principal Consultant for ICA Biotechnology, VP of Operations for Lumos Diagnostics from (2018-2022), VP of Operations for Versea Health (2022-2023) and Principal Consultant for Accalle Group (2022-Present). In addition, Mr. Phinney holds USPTO Patent 20050277185: Chemistry, Molecular Biology, and Microbiology Binding Assay Device and has presented Modification of a Commercial HIV-1 Enzyme Immunoassay for Identification of Recent HIV-1 Infection, at the annual Conference of Retrovirus and Opportunistic Infections. 


Mr. Phinney will serve for a minimum of six months and, pursuant to a Consulting Agreement with the Company, will be compensated with an option to purchase up to 2,000,000 shares of the Company's common stock registered on Form S-8 (the "Option Shares") vesting at a rate 1/6 of the Option Shares every 30 days. The foregoing summary of certain of the terms and conditions of the Consulting Agreement is qualified in its entirety by reference to the full text of the Consulting Agreement filed as Exhibit 10.1 hereto and is incorporated herein by reference.